Compared to the IV infusion of the blockbuster cancer drug Keytruda, subcutaneous Keytruda was able to reduce the time patients spent in the chemotherapy chair.

NEW YORK, March 27 (Reuters) - Merck & Co (MRK.N), opens new tab said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the ...

A dispute over a microscopic enzyme is threatening Merck & Co. plans to sell a new version of Keytruda, the cancer drug that generates nearly half of the company’s sales. Merck has been tweaking ...

When combined with trastuzumab and chemotherapy, treatment with pembrolizumab was associated with a statistically significant improvement in PFS and OS compared with placebo. The conversion to ...

March 5 (Reuters) - Merck's (MRK.N), opens new tab injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics (HALO.O ...

Merck’s (NYSE:MRK) injectable based on an enzyme developed by South Korea-based Alteogen is the company’s answer to the upcoming patent cliff for intravenously delivered Keytruda, which ...

How Does Keytruda Work for RCC? Some cancer cells have what are called checkpoint proteins known as PD-L1 on their cell surface. Some immune cells in our bodies called T cells have proteins on ...

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting negotiations next year under the Inflation Reduction Act. In a filing with ...

The committee based its decision on data showing the subcutaneous formulation of Opdivo was not inferior to the intravenous formulation.

Padcev plus Keytruda shows superior response and survival rates in first-line metastatic urothelial carcinoma treatment compared to chemotherapy. Padcev monotherapy provides clinical benefits in later ...